One-week losartan administration increases sodium excretion in cirrhotic patients with and without ascites

[Guest guest]

J Gastroenterol 2002;37(3):194-9

One-week losartan administration increases sodium excretion in cirrhotic

patients with and without ascites.

Yang YY, Lin HC, Lee WC, Hou MC, Lee FY, Chang FY, Lee SD

Department of Medicine, Taipei Veterans General Hospital and National

Yang-Ming University School of Medicine, Taiwan.

[Medline record in process]

BACKGROUND: Losartan, a highly selective angiotensin II type 1 receptor

antagonist, has been reported to have a significant portal hypotensive

effect in cirrhotic patients. A recent study also showed that losartan

exerted a dramatic natriuretic effect in preascitic cirrhosis. The influence

of losartan on renal hemodynamics and sodium homeostasis in cirrhotic

patients with ascites is unclear. This study was undertaken to evaluate the

renal effects of 1-week losartan treatment in cirrhotic patients with and

without ascites. METHODS: All 12 patients in the study received a daily oral

dose of 25 mg losartan for 7 consecutive days. Effective renal plasma flow,

urine volume, creatinine clearance, 24h urine sodium excretion and

fractional excretion of sodium, blood urea nitrogen, and serum creatinine

were measured before and after treatment. RESULTS: In cirrhotic patients

without ascites, creatinine clearance, 24-h urinary sodium excretion, and

fractional excretion of sodium were significantly increased after losartan

administration. Effective renal plasma flow and serum creatinine showed

almost no change after treatment. In cirrhotic patients with ascites,

creatinine clearance, 24-h urinary sodium excretion, fractional excretion of

sodium, and effective renal plasma flow were significantly increased after

losartan administration. In addition, the magnitudes of the increases in the

fractional excretion of sodium and in the 24-h urinary sodium excretion were

greater in cirrhotic patients with ascites than in those without ascites.

CONCLUSIONS: One-week treatment with losartan increases sodium excretion in

association with an improvement of renal function in cirrhotic patients with

and without ascites. The natriuretic effect was more profound in cirrhotic

patients with ascites than in those without ascites.

PMID: 11931532, UI: 21928503

[Guest guest]

J Gastroenterol 2002;37(3):194-9

One-week losartan administration increases sodium excretion in cirrhotic

patients with and without ascites.

Yang YY, Lin HC, Lee WC, Hou MC, Lee FY, Chang FY, Lee SD

Department of Medicine, Taipei Veterans General Hospital and National

Yang-Ming University School of Medicine, Taiwan.

[Medline record in process]

BACKGROUND: Losartan, a highly selective angiotensin II type 1 receptor

antagonist, has been reported to have a significant portal hypotensive

effect in cirrhotic patients. A recent study also showed that losartan

exerted a dramatic natriuretic effect in preascitic cirrhosis. The influence

of losartan on renal hemodynamics and sodium homeostasis in cirrhotic

patients with ascites is unclear. This study was undertaken to evaluate the

renal effects of 1-week losartan treatment in cirrhotic patients with and

without ascites. METHODS: All 12 patients in the study received a daily oral

dose of 25 mg losartan for 7 consecutive days. Effective renal plasma flow,

urine volume, creatinine clearance, 24h urine sodium excretion and

fractional excretion of sodium, blood urea nitrogen, and serum creatinine

were measured before and after treatment. RESULTS: In cirrhotic patients

without ascites, creatinine clearance, 24-h urinary sodium excretion, and

fractional excretion of sodium were significantly increased after losartan

administration. Effective renal plasma flow and serum creatinine showed

almost no change after treatment. In cirrhotic patients with ascites,

creatinine clearance, 24-h urinary sodium excretion, fractional excretion of

sodium, and effective renal plasma flow were significantly increased after

losartan administration. In addition, the magnitudes of the increases in the

fractional excretion of sodium and in the 24-h urinary sodium excretion were

greater in cirrhotic patients with ascites than in those without ascites.

CONCLUSIONS: One-week treatment with losartan increases sodium excretion in

association with an improvement of renal function in cirrhotic patients with

and without ascites. The natriuretic effect was more profound in cirrhotic

patients with ascites than in those without ascites.

PMID: 11931532, UI: 21928503